Literature DB >> 15329416

Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression.

Chih-Chuan Chang1, Jonathan D Heller, Jennifer Kuo, Ru Chih C Huang.   

Abstract

We previously reported that Sp1-dependent Cdc2 gene expression is inhibited by tetra-O-methyl nordihydroguaiaretic acid (M(4)N) and that M(4)N is likely responsible for causing growth arrest in M(4)N-treated transformed C3 cells. Here, we show that after M(4)N treatment and cell-cycle arrest, expression of the Sp1-dependent survivin gene, a member of the inhibitor of apoptosis family, is also suppressed, and the mitochondrial apoptotic pathway is activated. To confirm that inhibition of Cdc2 and survivin gene expression is necessary for M(4)N-induced growth arrest and apoptosis, we tested the effect of adding Cdc2 and survivin back to M(4)N-treated cells. Cell division was transiently restored in the presence of M(4)N after transfection of an exogenous Cdc2 gene copy under the control of the Sp1-independent cytomegalovirus promoter. Caspase-3 activation was also reduced by 50% and 75% in transiently and stably survivin-transfected C3 cells, respectively. The results suggest that M(4)N induces growth arrest and apoptosis by suppressing Cdc2 and survivin expression, which constitutes the cellular basis of its antitumoric action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329416      PMCID: PMC516554          DOI: 10.1073/pnas.0405407101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Transcriptional analysis of human survivin gene expression.

Authors:  F Li; D C Altieri
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  p34(Cdc2) kinase activity is excluded from the nucleus during the radiation-induced G(2) arrest in HeLa cells.

Authors:  G D Kao; W G McKenna; R J Muschel
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

3.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo.

Authors:  J D Heller; J Kuo; T C Wu; W M Kast; R C Huang
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

5.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.

Authors:  S Fukuda; L M Pelus
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

6.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

7.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.

Authors:  D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor.

Authors:  H Chen; J Campisi; R Padmanabhan
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

9.  Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.

Authors:  J N Gnabre; J N Brady; D J Clanton; Y Ito; J Dittmer; R B Bates; R C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.

Authors:  H Chen; L Teng; J N Li; R Park; D E Mold; J Gnabre; J R Hwu; W N Tseng; R C Huang
Journal:  J Med Chem       Date:  1998-07-30       Impact factor: 7.446

View more
  44 in total

Review 1.  Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Authors:  Jian-Ming Lü; Jacobo Nurko; Sarah M Weakley; Jun Jiang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2010-05

2.  Effects of shRNA targeting survivin on apoptosis of human retinoblastoma cell line Hxo-rb44 in vitro.

Authors:  Guojun Wang; Yanhua Hu; Pengcheng Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 3.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

Review 4.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

5.  Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jinbo Gao; Baoguo Ren; Brian S Zuckerbraun; Raja S Mahidhara; Quanhua Xing; Eva Pizzoferrato; John H Yim
Journal:  Cancer Lett       Date:  2011-12-23       Impact factor: 8.679

6.  BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

Authors:  J Hagenbuchner; U Kiechl-Kohlendorfer; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

7.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

8.  Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Authors:  R Tibes; K T McDonagh; L Lekakis; J M Bogenberger; S Kim; N Frazer; S Mohrland; D Bassett; R Garcia; K Schroeder; V Shanmugam; J Carpten; R T Hagelstrom; C Beaudry; D Von Hoff; T C Shea
Journal:  Invest New Drugs       Date:  2014-12-19       Impact factor: 3.850

9.  Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.

Authors:  Qinghui Wang; Kinsie E Arnst; Yi Xue; Zi-Ning Lei; Dejian Ma; Zhe-Sheng Chen; Duane D Miller; Wei Li
Journal:  Eur J Med Chem       Date:  2018-02-19       Impact factor: 6.514

10.  Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.

Authors:  Ross O Meyers; Joshua D Lambert; Nicole Hajicek; Alan Pourpak; John A Kalaitzis; Robert T Dorr
Journal:  Bioorg Med Chem Lett       Date:  2009-06-21       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.